| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 121.33 mm | 121.33 mm | 121.33 mm | 121.33 mm | 121.33 mm | 121.33 mm |
| Cash burn (monthly) | 747.67 k | 75.25 k | 7.09 mm | 1.35 mm | 1.97 mm | 4.02 mm |
| Cash used (since last report) | 3.01 mm | 302.83 k | 28.54 mm | 5.43 mm | 7.93 mm | 16.16 mm |
| Cash remaining | 118.32 mm | 121.03 mm | 92.79 mm | 115.89 mm | 113.40 mm | 105.17 mm |
| Runway (months of cash) | 158.3 | 1608.3 | 13.1 | 85.8 | 57.5 | 26.2 |
| 13F holders | Current |
|---|---|
| Total holders | 55 |
| Opened positions | 9 |
| Closed positions | 4 |
| Increased positions | 10 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 28.20 bn |
| Total shares | 28.81 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Novartis Pharma | 12.41 mm | $15.01 mm |
| Tang Capital Partners | 6.40 mm | $2.30 mm |
| LLY Eli Lilly and | 3.76 mm | $0.00 |
| venBio Global Strategic Fund | 2.54 mm | $21.05 mm |
| JHG Janus Henderson | 702.07 k | $6.32 bn |
| Tang Capital Management | 623.33 k | $5.59 bn |
| Perceptive Advisors | 426.29 k | $3.82 bn |
| Highbridge Capital Management | 406.25 k | $3.28 mm |
| Aquilo Capital Management | 381.80 k | $3.42 bn |
| Vanguard | 263.96 k | $2.37 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 Jan 25 | Scimeca Dario | Common Stock | Sell | Dispose S | No | Yes | 4.79 | 8,928 | 42.77 k | 24,353 |
| 22 Jan 25 | J. Jefferson Smith | Common Stock | Sell | Dispose S | No | Yes | 4.79 | 10,287 | 49.27 k | 87,440 |
| 21 Jan 25 | Michael Amoroso | Common Stock | Sell | Dispose S | No | Yes | 4.67 | 36,838 | 172.03 k | 107,087 |
| 20 Jan 25 | Scimeca Dario | Common Stock | Option exercise | Acquire M | No | No | 0 | 25,312 | 0.00 | 33,281 |
| 20 Jan 25 | Scimeca Dario | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 14,908 | 0.00 | 29,815 |
| 20 Jan 25 | Scimeca Dario | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 8,427 | 0.00 | 16,850 |
| 20 Jan 25 | Scimeca Dario | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,977 | 0.00 | 1,978 |
| 20 Jan 25 | John Alexander Kelly | Common Stock | Option exercise | Acquire M | No | No | 0 | 44,368 | 0.00 | 84,554 |
| 20 Jan 25 | John Alexander Kelly | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 26,575 | 0.00 | 53,150 |
| 20 Jan 25 | John Alexander Kelly | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 13,904 | 0.00 | 27,801 |
